Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin-angiotensin-aldosterone system inhibitors (RAASIs).
|
31119681 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
|
31493202 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome.
|
28849606 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.
|
30581499 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the efficacy of medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers has not been defined in TRC.
|
30859381 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperkalemia (HK) occurs often among patients with chronic kidney disease (CKD) and heart failure (HF) and those treated with renin-angiotensin-aldosterone system inhibitors (RAASI).
|
29667438 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A candidate gene approach has shown that common genetic variants of the renin-angiotensin-adrenergic pathway can also influence heart failure and may be associated with different outcomes.
|
20814312 |
2011 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess whether renin-angiotensin-aldosterone (RAA) system gene polymorphisms shown to be associated with alterations in the activity of the system, may predict cardiac function changes subsequent to initiating medical therapy in heart failure.
|
12031704 |
2002 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, half of the patients in all three age groups with heart failure and kidney disease received treatment with renin-angiotensin-system inhibitors; about two out of five patients received beta-blockers, while prescription rates of aldosterone inhibitors were low.
|
30187290 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Elderly heart failure with reduced ejection fraction patients (≥75 years) received significantly fewer beta-blockers (77.8% vs. 84.2%), renin-angiotensin system inhibitors (75.2% vs. 89.7%), mineralocorticoid receptor antagonists (50.6% vs. 59.6%) and ivabradine (2.9% vs. 9.3%), but significantly more diuretics (88.1% vs. 72.6%) compared to patients aged less than 60 years (<i>P</i><sub>for all trends</sub> < 0.01).
|
30866680 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies on polymorphisms of the renin-angiotensin-aldosterone system (RAAS), adrenergic receptor polymorphisms, endothelin (receptor) polymorphisms, and a group of miscellaneous polymorphisms that may be involved in the development or phenotypic expression of heart failure will be reviewed.
|
15545741 |
2005 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery.
|
30367208 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction.
|
29952095 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs throughout the continuum of cardiovascular disease spanning from hypertension to heart failure with reduced ejection fraction.
|
31786973 |
2020 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin-aldosterone system inhibitor use was associated with lower risk of heart failure (hazard ratio, 0.79; 95% confidence interval, 0.67-0.97) and death (hazard ratio, 0.78; 95% confidence interval, 0.67-0.90), regardless of severity of CKD .
|
30371331 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results of the subgroup analysis suggested that the intermediate-acting dihydropyridine calcium channel blocker was associated with higher risk of heart failure (RR: 1.30, [95% CI, 1.08-1.56], P = .005) and AMI (RR: 1.50, [95% CI, 1.01-2.22], P = .043) compared to renin-angiotensin system blockers and a trend toward higher risk of AMI (RR: 1.17, [95% CI, 0.99-1.38], P = .064) compared to conventional therapy, including β-blockers and diuretics.
|
29739234 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, a gene polymorphism of the renin-angiotensin system in development of heart failure was identified as a modifier gene.
|
23907713 |
2014 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with chronic kidney disease (CKD) and/or diabetic nephropathy with or without heart failure (HF), allowing the majority of patients to continue receiving renin-angiotensin-aldosterone system (RAAS) inhibitors (drugs that inhibit the renal excretion of potassium) for up to 52 weeks.
|
30030701 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Correlation with HF hospitalization improved when analyses were restricted to trials completed in the last decade (>2010; r = 0.92; p = 0.0095), using N-terminal pro-B-type NP assays (r = 0.65; p = 0.06), and evaluating inhibitors of the renin-angiotensin-aldosterone system (r = 0.97; p = 0.0002).
|
29501807 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with heart failure are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone system inhibitor (RAASi) agents.
|
30160541 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin-angiotensin-aldosterone system increases the risk of hyperkalemia.
|
27842179 |
2017 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Resuming renin-angiotensin blockade at discharge home was associated with a decreased risk of heart failure within 30 days of surgery (0.3% vs 11.8% of cases) and stage IV/V chronic kidney disease at last followup (2.6% vs 25.5%, each p <0.001).
|
27746281 |
2017 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In older patients (70 ± 7 years) with chronic well-compensated heart failure with preserved ejection and controlled blood pressure, 6 months treatment with aliskiren (direct renin inhibitor) showed non-significant trends for modest improvements in peak exercise oxygen consumption (14.9 ± 0.2 mL kg<sup>-1</sup> min<sup>-1</sup> versus 14.4 ± 0.2 mL kg<sup>-1</sup> min<sup>-1</sup>; P = .10, trend) and ventilatory anaerobic threshold (888 ± 19 mL/min versus 841 ± 18 mL/min; P = .08).
|
29910050 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We tested for a difference in prevalence of 10 renin-angiotensin-aldosterone system (RAAS)-related gene polymorphisms between a homogenous population of HF patients and healthy controls.
|
18279468 |
2008 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DD allele frequency is lower in Chinese, but the M235T variant of the angiotensinogen gene is more common in Chinese than whites; it is not known to what extent polymorphisms of the renin-angiotensin system affect clinical status or prognosis in Chinese patients with heart failure.
|
10097225 |
1999 |